476-24 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants with Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC 8)

Overview

“A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy”

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.

The purpose of this study is to learn more about how durvalumab and domvanalimab given after completion of concurrent chemoradiotherapy (chemotherapy and radiation at the same time) in unresectable stage III NSCLC might provide benefit to participants and also to better understand the studied disease and associated health problems. Participants enrolled in this study, you may either receive:

• Durvalumab and domvanalimab, OR:
• Durvalumab and placebo (an inactive substance)

The use of the combined drugs is investigational. “Investigational” means that durvalumab and domvanalimab in combination has not been approved by the US Food and Drug Administration (“FDA”) for use as a prescription or over-the-counter medication.